Skip to main
PRTA

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Prothena Corp PLC is poised for a positive financial outlook due to the potential to earn up to $105 million in milestone payments by 2026, attributed to advancements in their partnerships with Novo Nordisk and Bristol-Myers Squibb. The company’s investigational therapeutics, including Coramitug and PRX019, show promising early results with favorable reductions in amyloid levels, despite some safety concerns. Additionally, the favorable tolerance profile of PRX012, alongside a low incidence of injection-site reactions, underscores the overall potential of Prothena's clinical pipeline in addressing significant unmet medical needs.

Bears say

Prothena Corp PLC is facing a negative outlook primarily due to its continued net losses, which are expected to persist until product approval and commercialization, likely extending through the early phases of product launch. The company's need to raise additional capital in the short term could have uncertain and potentially dilutive effects on shareholder value, hampering investor confidence. Moreover, regulatory risks present further challenges, as changes in the regulatory stance on specific diseases or molecule classes could introduce new barriers to approval and complicate the commercialization process.

Prothena (PRTA) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 9 analysts, Prothena (PRTA) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.